<DOC>
	<DOCNO>NCT00755222</DOCNO>
	<brief_summary>This study evaluate safety effectiveness AA4500 improve impact Peyronie 's disease quality life improve penile curvature men Peyronie 's disease</brief_summary>
	<brief_title>The Safety Effectiveness AA4500 Subjects With Peyronie 's Disease</brief_title>
	<detailed_description>A Phase 2b randomize , double-blind , placebo-controlled study AA4500 treatment subject Peyronie 's disease . During screen period , subject physical examination include body weight height , vital sign measurement , 12-lead electrocardiogram ( ECG ) , clinical laboratory test . Medical history , prior concomitant medication , demographic data record .</detailed_description>
	<mesh_term>Penile Induration</mesh_term>
	<criteria>Heterosexual male ≥ 18 year age In stable relationship partner/spouse least 3 month screen Have diagnosis Peyronie 's disease least 6 month first dose study drug Have penile curvature least 30° dorsal , lateral , dorsal/lateral plane Have functional difficulty relate Peyronie 's disease ( eg , difficulty intromission erectile dysfunction ) Be judge good health base upon result medical history , physical examination laboratory profile Voluntarily sign inform consent agreement approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) . The subject must also sign authorization form allow disclosure protect health information . The protected health information authorization form inform consent form may integrate form may separate form , depend institution Be able complete understand various rating instrument Have average three successive blood pressure reading ≥ 160/100 mmHg screen Day 1 assessment Severe pain penile palpation Any following condition : Chordee presence absence hypospadias Thrombosis dorsal penile artery Infiltration benign malignant mass result penile curvature Infiltration infectious agent , lymphogranuloma venereum Ventral curvature cause Presence sexually transmit disease Known Hepatitis B C Known immune deficiency disease positive human immunodeficiency virus ( HIV ) Previously undergone surgery Peyronie 's disease Penile curvature le 30° great 90° Failed rigid erection pharmacological stimulation vasoactive injection Prostaglandin E1 10 20 µg , , opinion investigator , sufficient accurately measure subject 's penile deformity Had calcify plaque evident appropriate radiographic evaluation , penile xray , penile ultrasound . Noncontiguous stipple calcium acceptable inclusion Had isolate hourglass deformity penis without curvature Had plaque cause curvature penis locate proximal base penis , injection local anesthetic would interfere injection AA4500 plaque Received alternative medical therapy Peyronie 's disease administer intralesional route ( include , limited , steroid , verapamil , naturally occur low molecular weight protein , interferonα2b ) within 3 month first dose study drug plan use medical therapy time study Received alternative medical therapy Peyronie 's disease administer oral ( include , limited , vitamin E ( &gt; 500IU ) , potassium aminobenzoate [ Potaba ] , tamoxifen , colchicine , pentoxifylline , overthecounter erectile dysfunction medication , steroidal anti inflammatory drug ) topical route ( include , limited , verapamil apply cream ) within 4 week first dose study drug plan use medical therapy time study Used mechanical type device correction Peyronie 's disease within 2week period screen plan use device time study Used mechanical device induce passive erection within 2week period screen plan use device time study Significant erectile dysfunction fail respond oral treatment phosphodiesterase type 5 ( PDE5 ) inhibitor Recent history stroke , bleeding , medical condition , investigator 's opinion would make subject unsuitable enrollment study Unwilling unable cooperate requirement study include completion schedule study visit Received investigational drug treatment within 30 day first dose study drug Allergy collagenase excipient AA4500 Allergy concomitant medication require per protocol Received anticoagulant medication ( except ≤ 165 mg aspirin daily ≤ 800 mg overthecounter NSAIDS daily ) 7 day dose study drug Received doxycycline tetracycline derivative 7 day dose study drug plan use drug within 2 day injection study drug Received collagenase treatment within 30 day first dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Peyronie 's disease</keyword>
	<keyword>penile plaque</keyword>
	<keyword>penile curvature</keyword>
</DOC>